Figure 2.

Molecular pathology findings. A) IntegrativeGenomics-Viewer of KRAS sequencing by MSK-IMPACT assay from original tumor shows 25% of bidirectional reads show a KRAS c.35G>T (p.G12V) mutation in reverse direction in tumor (top, arrow pointing to total and nucleotide-specific reads) but not matched normal (below, arrow pointing to total and mutant specific reads). B) Confirmatory Sequenom Mass Spectrometry (arrow) results show the wild type (WT) KRAS peak, as well as the same mutant (MUT) peak (c.35G>T) in the GIST recurrence. C) Log ratio of copy number alterations graph show MDM2 and IGF1 amplification relative to normal tissue, with fold changes of 3.3 and 3.2, respectively. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]